Request [NYSE American:CYBN]

" TORONTO–[Cybin Inc.] [NEO:CYBN] (NYSE American:CYBN) Cybin or the Company, a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics."

You need for vote for yourself aswell :+1:t2:
I’ll put a vote down maybe you’ll like to look at thread on here for $dea and maybe vote on that stock :thinking::rofl:

1 Like

Thanks Lenny!

1 Like